Alkermes ALKS
NASDAQ ALKS
$45.40 -0.09 (-0.20%)
As of: Sep 9, 2026 · 3:59 PM EDT

Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)

Alkermes' (ALKS) quarterly Cash from Investing Activities came in at -$2.4 million in Q2 2026, up 91.75% year-over-year from -$1.3 million in Q2 2025, and up 99.88% quarter-over-quarter from -$2.1 billion in Q1 2026.

Analysis

Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Cash from Investing Activities for 17 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Cash from Investing Activities rose 91.75% year-over-year to -$2.4 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 1130.68% decrease from a year earlier, with the FY2025 full-year figure at $295.5 million, up 365.48% from the prior year.
  • Cash from Investing Activities was -$2.4 million for Q2 2026 at Alkermes, up from -$2.1 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $322.3 million in Q4 2025 and troughed at -$2.1 billion in Q1 2026.
  • A 5-year average of -$105.9 million and a median of -$10.3 million in 2024 frame the typical range for Cash from Investing Activities.
  • Across the five-year window, Cash from Investing Activities surged 3838.54% in 2022 and plunged 22919.16% in 2026, its largest moves.
  • Over 5 years, Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then jumped by 33.87% to -$13.9 million in 2024, then jumped by 2423.21% to $322.3 million in 2025, then slumped by 100.75% to -$2.4 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$2.4 million (Q2 2026), -$2.1 billion (Q1 2026), and $322.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn -1.11 Bn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn -1.20 Bn
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn -5.60 Bn
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn -3.11 Bn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 2.11 Bn
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn -424.26 Mn
7 Revolution Medicines 43.79 Bn 43.79 Bn - -1.66 Bn
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn -51.79 Mn
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn 87.50 Mn
10 Alkermes 7.58 Bn 6.92 Bn 397.90 Mn -2.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.41 Mn
Mar 31, 2026 -2.08 Bn
Dec 31, 2025 322.35 Mn
Sep 30, 2025 -6.74 Mn
Jun 30, 2025 -29.21 Mn
Mar 31, 2025 9.10 Mn
Dec 31, 2024 -13.88 Mn
Sep 30, 2024 -109.33 Mn
Jun 30, 2024 51.85 Mn
Mar 31, 2024 -39.95 Mn
Dec 31, 2023 -20.98 Mn
Sep 30, 2023 -119.36 Mn
Jun 30, 2023 120.85 Mn
Mar 31, 2023 72.85 Mn
Dec 31, 2022 27.74 Mn
Sep 30, 2022 8.90 Mn
Jun 30, 2022 -40.54 Mn
Mar 31, 2022 -60.64 Mn
Dec 31, 2021 -742,000.00
Sep 30, 2021 -31.71 Mn